What is market-access intelligence?

Understanding whether a product can actually reach the patients it is for — formulary position, reimbursement status, and the competitors already occupying that position. It is distinct from market size, which tells you the opportunity without telling you whether you can serve it.

Why does monitoring need alerts?

Because competitive and access changes do not wait for a reporting cycle. Benchmarking and monitoring with alerts means you learn about a formulary change or a competitor move when it happens, rather than in the following quarter review.

What does "connected experiences" mean here?

That the same intelligence reaches commercial, medical and market-access teams from one source rather than as three separately commissioned reports. Three reports built from three extracts will disagree, and the disagreement consumes more time than the analysis.

How does this relate to prescription analytics?

Prescription analytics is the observational half — what is actually written and dispensed. Market and competitor intelligence is the strategic half. The first is evidence and the second is interpretation, and a strategy built without the first is an opinion.

Is this only for large pharmaceutical companies?

No, though the scale of data favours them. Smaller organisations typically need narrower questions answered — a single market, a single therapy area — which is a smaller engagement rather than a different capability.

Pharmaceutical & Related Segments

Segmentation in Pharmaceutical Industry – An Overview

Pharma Intelligence stocks a spectrum of pharmaceutical research and analytics tools to support you recognize and assessing strategic possibilities inside the global pharmaceutical market.

With pharmaceutical data analytics from the major industry driving specialists in the pharma business, you will have access to competitor and market access intelligence and the capability to benchmark and monitor with alerts.

Technology Partner for Digital Transformation in Life Sciences and Healthcare Businesses Globally

Delivering connected experiences across your business

The Pharmaceutical and life sciences business landscape is swiftly evolving. Let us support you efficiently in enduring the new obstacles you're encountering today to ensure your organization remains stable and profitable. Using established data, we deliver you insights and an advantage in bringing your products to market.

We analyze market developments and what's working—and not working—in how commercial models react. Nano Health's assets, connected with our industry expertise, functional knowledge, and consulting methodologies, have benefited many retail leaders to drive forward successfully in a shifting landscape.

Strengthen operational efficiency

Pharmaceutical and med device businesses necessitate achieving operational efficiency to ensure their progress. Commencing with the assumption that operations can and should be a strategic capability, Nano Health helps clients to drive tangible performance improvements in operations and supply chain while lessening risk. In alliance with each client's business objectives, our teams support building continual capabilities for perpetual and transformative improvements to the bottom line.

Revitalizing your journey to digital healthcare

What will you get with a demo session?

A 15-minute demo with our product specialists will help you unlock all of Nano Health's potential. We will communicate with you shortly to book a demo at a suitable time for you.

Request a demo

How this works with the rest of the suite

NANO Rx Insight
Market and competitor intelligence begins with what is actually being prescribed and dispensed.
NANO IDDK
Comparing products across markets requires a drug reference that means the same thing in each.
NANO PBM
Market access is decided largely in benefit design, which is where a formulary position is won or lost.
NANO PTTS
Distribution and serialization data describe where a product actually went, which no market report does.

Frequently asked questions

What is market-access intelligence?: Understanding whether a product can actually reach the patients it is for — formulary position, reimbursement status, and the competitors already occupying that position. It is distinct from market size, which tells you the opportunity without telling you whether you can serve it.
Why does monitoring need alerts?: Because competitive and access changes do not wait for a reporting cycle. Benchmarking and monitoring with alerts means you learn about a formulary change or a competitor move when it happens, rather than in the following quarter review.
What does "connected experiences" mean here?: That the same intelligence reaches commercial, medical and market-access teams from one source rather than as three separately commissioned reports. Three reports built from three extracts will disagree, and the disagreement consumes more time than the analysis.
How does this relate to prescription analytics?: Prescription analytics is the observational half — what is actually written and dispensed. Market and competitor intelligence is the strategic half. The first is evidence and the second is interpretation, and a strategy built without the first is an opinion.
Is this only for large pharmaceutical companies?: No, though the scale of data favours them. Smaller organisations typically need narrower questions answered — a single market, a single therapy area — which is a smaller engagement rather than a different capability.